

CURRICULUM VITAE
Edward D. French, Ph.D.
Professor *Emeritus* in Pharmacology
The University of Arizona College of Medicine
Updated July 2023

CONTACT INFORMATION:

E-Mail: efrench@arizona.edu
Telephone: 520-991-7273
Website: www.edwarddfrench.com

EDUCATION:

1969	B.S.	Zoology, California State University Long Beach, California
1976	Ph.D.	Pharmacology, University of California (UCLA) Los Angeles, California

RESEARCH INTERESTS:

Delineation of the sites and mechanisms by which drugs of abuse and stress alter central nervous system function and behavior with particular emphasis on dopamine, glutamate, and GABA neurotransmission.

PROFESSIONAL AND ACADEMIC EXPERIENCE:

2018-present	Professor Emeritus, Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ
2001-2018	Professor, Department of Pharmacology, The University of Arizona, Tucson, AZ
2004-2010	Chairperson, Graduate Program in Medical Pharmacology, The University of Arizona.
1996-2005	Chairperson, Interdisciplinary Graduate Program in Pharmacology and Toxicology, Graduate College, The University of Arizona.
2001-present	Professor, Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, Arizona.
1991-2001	Associate Professor, Tenured, Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, Arizona.

- 1988 - 1991 Associate Professor, Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, Arizona.
- 1988 -1998 Associate Professor, Principal Faculty Member, Program in Neuroscience, The University of Arizona, Tucson, Arizona.
- 1986 - 1988 Research Associate Professor, Neuroscience Program, Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, Maryland.
- 1986 - 1987 Acting Chief, Neuroscience Program, Maryland Psychiatric Research Center, Baltimore, Maryland.
- 1986 - 1988 Associate Professor of Pharmacology, Secondary appointment, Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, Baltimore, Maryland.
- 1980 - 1986 Research Assistant Professor, Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, Maryland.
- 1979 - 1980 Alexander von Humboldt Research Fellow, Max-Planck-Institute for Psychiatry, Neuropharmacology Section, Munich, Germany.
- 1978 - 1979 Research Associate, Arthur V. Davis Center for Behavioral Neurobiology, The Salk Institute, San Diego, California; Supervisor: Dr. Floyd E. Bloom.
- 1976 - 1978 Postdoctoral Research Fellow, Arthur V. Davis Center for Behavioral Neurobiology, The Salk Institute, San Diego, California; Supervisor: Dr. Floyd E. Bloom.
- 1975 - 1976 Research Assistant, Department of Pharmacology, University of California, School of Medicine, Los Angeles, California; Supervisor: Dr. Robert George.
- 1973 - 1975 Teaching Assistant, Department of Pharmacology, University of California, School of Medicine, Los Angeles, California.
- 1973 - 1975 Consultant, Over-the-Counter Drug Evaluation Committee, Food and Drug Administration; Supervisor: Dr. J. Weldon Bellville, University of California, School of Medicine, Los Angeles, California.

- 1969 - 1970 Biological/Biochemical Laboratory Technician, Veterans Administration Hospital, Long Beach, California; Supervisor: Dr. H. Labitzke.
- 1990 to present: Consultant and expert witness in criminal and civil litigation in city, state, county, and federal courts for plaintiffs, prosecutors, and defense counsel. Evaluate medical documentation, pharmacology and toxicology records and lab findings, and transcripts, and supply written opinions and expert testimony to courts upon request.

Military Service:

- 1969 - 1975 United States Army Reserve, Medical Detachment, Specialist 5, Honorable Discharge.

HONORS, AWARDS, AND FELLOWSHIPS:

- 2014 Outstanding Achievement in Teaching by the Cardio, Pulmonary & Renal Block, Year 1, University of Arizona Medicine Curriculum
- 2012 Inducted into the Academy of Medical Education Scholars, The University of Arizona College of Medicine
- 2010 Vernon & Virginia Furrow Award, AMES Grant for Medical Education Research
- 2005 Vernon & Virginia Furrow Award for "Excellence in Innovation in Teaching".
- 2003 Basic Science Educator of the Year, College of Medicine.
- 2002 Vernon and Virginia Furrow Award for "Excellence in Innovation in Teaching".
- 1997-2002,
2005 Dean's List for Excellence in Teaching Basic Science for Medical Students.
- 1998 Basic Science Educator of the Year, College of Medicine.
- 1998 Dean's Teaching Scholar, College of Medicine.
- 1998 Vernon & Virginia Furrow "Innovations in Medical Education" Grant.
- 1998 Award for Outstanding Achievement in Teaching in the Basic Sciences, Pharmacology Course, College of Medicine.

- 1982 - 1984 Pharmaceutical Manufacturers Association Foundation, Research Starter Grant Award.
- 1979 - 1980 Alexander von Humboldt Foundation Research Fellowship.
- 1979 NATO Postdoctoral Fellowship awarded but declined.
- 1976 - 1978 National Research Service Award, National Institutes of Health.
- 1974 - 1975 National Institute of Mental Health Predoctoral Trainee.
- 1970 - 1974 National Science Foundation Predoctoral Fellowship.
- 1969 Honors Graduate, California State University at Long Beach.

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

Society for Neuroscience, U.S.A.
American Society for Pharmacology and Experimental Therapeutics (ASPET)
International Brain Research Organization

EDITORIAL TASKS:

Ad Hoc Reviewer:

Alcoholism, Clinical and Experimental Research	Neuroscience Letters
British Journal of Pharmacology	Neuropsychopharmacology
Cell Biology & Toxicology	Neurotoxicology & Teratology
Drug and Alcohol Dependence	Pharmacol Biochem & Behav
Journal of Clinical Psychiatry	Physiology and Behavior
Journal of Neurochemistry	Psychopharmacology
Journal of Neuroscience	Regulatory Peptides
Journal of Pharmacology & Experimental Therapeutics	Science
Life Sciences - Pharmacology Letters	Substance & Alcohol
Neuropsychopharmacology	Actions/Misuse
Molecular Neurobiology	Synapse
Neurobiology of Aging	

Editorial Advisory Board: Life Sciences, 1989 - 1993

Ad Hoc Grant Reviewer:

Center for Scientific Review, National Institutes of Health
National Science Foundation
Veterans Administration, Career Development Program

TEACHING

The University of Arizona, College of Medicine

Drugs of Abuse 445-545-on line distant learning-3 units—Course Co-Director
2016-2017

Cardiovascular, Pulmonary and Renal Block, Arizona Med, Director 2007- 2015

Introduction to Pharmacology 412/512, Central Nervous System Medications,
2012-2018; Autonomic Nervous System 2014-2018.

Pharmacology of Chemotherapeutics, Endocrine and Immune System Drugs
601B, Director 2014-2018

Pharmacological Basis of Therapeutics 502, Co-Director, Central Nervous
System Medications, 2011-2013

Pharmacological Basis of Therapeutics 501A – Central Nervous System
Medications, 1988-2007

Pharmacological Basis of Therapeutics 501/801
Course Director; 1993-2007

1995-2007: Autonomic Pharmacology - 8 hrs.
Antipsychotic Drugs - 2 hrs
Antidepressant Drugs - 2 hrs
Anticonvulsant Drugs - 2 hrs
Small Group Problem Sets - 16 hrs

1993-1994 Introduction to Pharmacology - 1 hr
Anticonvulsants - 2 hrs
Antipsychotic Drugs - 2 hrs
Antidepressant Drugs - 2 hrs
Patient Oriented Problem Solving - 6 hrs

1992-1993 Antipsychotic Drugs - 2 hrs
Antidepressant Drugs - 2 hrs
Patient Oriented Problem Solving - 6 hrs.

1990-1992 Antipsychotic Drugs - 1.5 hrs
Antidepressant Drugs - 1.5 hrs
Patient Oriented Problem-Solving Session on:
“Treatment of Essential Hypertension” - 3 hrs

1989-1990 Antipsychotic Drugs - 1.5 hrs
Antidepressant Drugs - 1.5 hrs
Patient Oriented Problem Solving - 3 hrs.

1988-1989 Patient Oriented Problem Solving

Neurobiology of Drugs of Abuse 445/545

Course Co-Director; 1995

Drug Use and Abuse - 1.5 hrs
Neurotransmission - 1.5 hrs
Reward Pathways - 1.5 hrs
Methods to Evaluate Drugs of Abuse - 3 hrs
Phencyclidine - 1.5 hrs
Cocaine - 3 hrs
Amphetamine - 1.5 hrs

Human Neurosciences 605/805

Course Co-Director; 1990-1992

1996-1999 Reward Systems and Addiction - 1 hr
1994-1995 Synaptic Transmission - 1 hr
Mechanisms of Reward (and Drugs of Abuse) - 3 hrs
1993-1994 Synaptic Transmission - 1 hr
Monoamine Pathways - 1 hr
Drugs of Abuse - 2 hrs
1992-1993 Limbic system - 2 hrs
Drugs of Abuse - 2 hrs
1988-1989 Psychomotor Stimulants - 1 hr

Elective Enrichment, College of Medicine

Co-Coordinator; 1998

What is Anesthesia?

Neuropharmacology 653

1995 Drugs of Abuse - 3 hrs
1993-1994 Synaptic Transmission - 1 hrs
Monoamine Pathways - 1 hr.
Drugs of Abuse - 2 hrs
1990-1992 Drugs of Abuse I - 1.5 hrs
Drugs of Abuse II - 1.5 hrs
Neuropharmacology of Psychiatric Disorders - 1.5 hrs
1989-1990 Electrophysiology of Synaptic Transmission I - 1.5 hrs
Electrophysiology of Synaptic Transmission II - 1.5 hrs.
Drugs of Abuse I - 1.5 hrs
Drugs of Abuse II - 1.5 hrs

1988-1989 Neuropharmacology of Psychiatric Disorders - 1.5 hrs
Drugs of Abuse I - 1.5 hrs
Drugs of Abuse II - 1.5 hrs

Psychopharmacology Postgraduate Course, Department of Psychiatry
2000-present: Neurobiology in Psychopharmacology - 1 hr

Arizona Health Science Center, Mini-Med School, Office of Public Affairs
2001: Drugs of Abuse: It's a Brain Thing

Introduction to Pharmacology & Toxicology Research 586A
1992-1997

Introduction to Pharmacology 620
1990-1995 Excitable Cells and Tissues - 3 hrs
1999-2000 Synaptic Transmission - 3 hrs
1991 Neuropharmacology of Drugs of Abuse

Neurology Residency Program
1996-2000 Mechanisms of Antiepileptic Drugs

Bridge Program, College of Medicine
1996-1998 Mechanisms of Drug Reward

National Institutes of Health Summer Minority Program
1997-2001 How to get into Graduate School

University of Maryland

Recent Advances in Pharmacology & Toxicology 431
1985 Endogenous Basis of Anxiety - 1.5 hrs

Psychiatry Residency Program: Neural Basis of Psychiatric Illness
1986 Anatomic Basis of Human Behavior 1.5 hrs

Psychiatry Residency Program: Biological Basis of Psychiatric Illness
1987 Anatomic Organization in Brain - 1.5 hrs
Electrophysiological Aspects of Neuronal Function - 1.5 hrs

Other

Continuing Medical Education Program, Spring Grove Hospital Center, Baltimore
Maryland
1984 Drug-induced Psychosis - 2 hrs

University of California, Department of Pharmacology
1978 Teaching Assistant for Laboratory Portion of Pharmacological Basis
of Therapeutics.

TUTORIAL TEACHING & RESEARCH GUIDANCE

University of Maryland

Supervised Research Projects of:

Caterina Aldino, Ph.D., 3/81 - 2/82
Annamaria Vezzani, Ph.D., 4/83 - 1/84
Raimin Parsey, 5/87 - 9/87
Melinda Smith, 5/87 - 9/87

The University of Arizona

Postdoctoral Trainees:

Angelo Ceci, Ph.D., 3/87 - 12/88
Anna Mura, Ph.D., 2/91 - 12/93
Ting Wang, M.D., 5/91 - 12/95
Ruoyan Yin, M.D., 6/96 - 1/2000
Greg Gerdeman, Ph.D., 6/03 – 6/06
Jason Schechter, Ph.D., 6/04 – 6/06

Thesis Advisor:

J. Tim Harlan, M.S., Dept. of Pharmacology, 1/88 - 9/90
Stefanie Levenson, Dept. of Pharmacology, 3/88 - 5/90
Jing-Yang Lin, M.A., Dept. of Psychology, 1/88 - 9/90
Debra Simms, M.A., Dept. of Psychology, 1/88 - 9/90
Art Riegel, M.S. Dept. of Pharmacology, 9/95-1/98
Xiaofang Wu, M.S. Dept. of Pharmacology 9/95-12/98
Art Riegel, Ph.D. Dept. of Pharmacology 6/98-6/2001
Karin Sandoval, Ph.D. Dept. of Pharmacology 6/2000-6/04

Thesis and Dissertation Committees:

Committee Member for:

Jay Coggan, Ph.D., 1992, Pharmacology & Toxicology
Rita Ware, Ph.D., 1992, Pharmacology & Toxicology
Paula Witt, Ph.D., 1993, Candidate, Pharmacology & Toxicology
Cheryl Harrington, M.S., 1994, Neuroscience
Jiemen Shen, Ph.D., 1995, Neuroscience
Hong-Bing Wei, Ph.D., 1995, Pharmacology & Toxicology
Wiam Khadra, M.S., 1995, Pharmacology/Toxicology Perfusion Sciences
Lynette Heslet, Ph.D., 1996, Psychology
Faith Palas, M.S., 1997, Pharmacology/Toxicology Perfusion Sciences

Jim Bourland, Ph.D., 1997, Pharmacology & Toxicology
Mike Nichols, Ph.D., 1997, Pharmacology & Toxicology
Ed Bilsky, Ph.D., 1997, Pharmacology & Toxicology
Todd Anthony, Ph.D., 1998, Pharmacology & Toxicology
Jason Lashbrook, M.S., 1998, Pharmacology & Toxicology
Curt Jablonowski, M.S., 1998, Pharmacology & Toxicology
Di Bian, Ph.D., 1999, Pharmacology & Toxicology
C.J. Kovelowski, Ph.D., 1999, Pharmacology & Toxicology
Connie Kim, M.S., 1999, Pharmacology & Toxicology
D. Bradford Sanders, M.S., 2000, Pharmacology & Toxicology, Perfusion Program
Stefan Proniuk, Ph.D., 2001, Pharmaceutical Sciences
Sandra Wegert, Ph.D., ABD, Pharmacology & Toxicology
Jennifer Martin, M.S., 2001, Pharmacology & Toxicology
Ken Witt, Ph.D. 2001, Pharmacology & Toxicology
Mohab Ibrahim, M.S., 2002 - Ph.D., 2004, Pharmacology & Toxicology
Cynthia Gentry, Ph.D., 2002 Pharmacology & Toxicology
Lou Gardell, Ph.D., 2002 Pharmacology & Toxicology
Tatiana Sandoval-Guzman, Ph.D., 2003, Program in Neuroscience
Yvonne Pak, Ph.D. 2004, Pharmaceutical Sciences
Renee Ingham, M.S., 2003, Pharmacology & Toxicology, Perfusion Program
Chris Pierce, M.S., 2004, Pharmacology & Toxicology, Perfusion Program
Colin Zappone, Ph.D., 2004, Program in Neuroscience
Douglas Morrison, Ph.D., 2004, Epidemiology
Victoria Dotson, M.S., 2004, Pharmacology & Toxicology, Perfusion Program
Ruizhong Wang, Ph.D., 2005, Pharmacology & Toxicology
Yanhua Xie, Ph.D., 2005, Pharmacology & Toxicology
Vincent Hau, Ph.D., 2005, Pharmacology & Toxicology
Qingmin Chen, Ph.D., 2006, Pharmacology & Toxicology
Wenhong Guo, M.S., 2006, Pharmacology & Toxicology
Dave Herman - Ph.D., 2006, Program in Neuroscience
Wenjun Zhang - Ph.D., 2006, Pharmacology & Toxicology
Katherine Horak - Ph.D., 2006, Pharmacology & Toxicology
Matt McReynolds, M.S., 2007, Medical Pharmacology, Perfusion Program
Michael LeNario, M.S., 2007 Medical Pharmacology, Perfusion Program
Ricky Chang, M.S., 2007, Medical Pharmacology, Perfusion Program
Nicola Stagg, Ph.D., 2007, Pharmacology & Toxicology
Timothy Marshall, Ph.D., 2007, Medical Pharmacology
Melissa Brym - Ph.D., 2007, Pharmacology & Toxicology
Anna Vardanyan, Ph.D., 2008, Medical Pharmacology
Marina Vardanyan, Ph.D., 2008, Medical Pharmacology
Kristyn Kurban, M.S., 2008, Perfusion Program
Emily Hirleman, M.S., 2008, Perfusion Program

Stacy Dunaway, M.S., 2008, Perfusion Program
Jiyang Ren, Ph.D. 2009, Medical Pharmacology
Anthony Platis, M.S., 2009 Medical Pharmacology, Perfusion Program
Derek Moore, M.S., 2009, Medical Pharmacology, Perfusion Program
Rebecca Edelmayer, Ph.D., 2009, Medical Pharmacology
Christopher Campos, Ph.D. 2009, Medical Pharmacology
Kate Lindborg, Ph.D. 2010, Physiological Sciences
Marie Fouts, M.S., 2010, Medical Pharmacology, Perfusion Program
Elisa Slack, M.S., 2010, Medical Pharmacology/Perfusion Program
Crista Lickteig, 2011, Medical Pharmacology, Perfusion Program
Rowena Campbell, Ph.D. 2011, Medical Pharmacology
Aimen Kasabeth, Ph.D., 2011, Program in Neuroscience
Hamid Bagdishi, M.S., 2012, Medical Pharmacology
Lucy Sanchez-Covarrubias, Ph.D., 2013, Medical Pharmacology
Nadia Corral-Frias, Ph.D., 2013, Program in Neuroscience
Bo Lian, Ph.D., 2013, Pharmaceutical Sciences
Beenish Majeed, Ph.D., 2014, Medical Pharmacology
David Skinner, Ph.D. 2014, Medical Pharmacology
Diana Meske, Ph.D. 2015, Medical Pharmacology
Lauren Slotsky, Ph.D. 2015, Medical Pharmacology
Samantha Behunin, Ph.D. 2015, Physiological Sciences
Alex Sandweiss, Ph.D., 2016, Medical Pharmacology
Kayla Gardner, M.S. 2016, Medical Pharmacology, Perfusion Program
Jennifer Arriola, M.S. 2016, Medical Pharmacology, Perfusion Program
Arturo Balajadia, M.S. 2016, Medical Pharmacology, Perfusion Program
Thanh Huynh, M.S., 2017, Medical Pharmacology, Perfusion Program
Lusine Gomstain, Ph.D. 2018, Medical Pharmacology
Mitchell Bartlett, M.D./Ph.D, 2019 Medical Pharmacology
Hong Zhang, Ph.D., Medical Pharmacology
Alysha Swanson, M.S., 2020 Medical Pharmacology, Perfusion Program

Graduate Student Advisor:

Rita Ware
Todd Vanderah
Wanda Haughlam
Ty Abel, Program in Neuroscience, laboratory rotation, 1/89 - 5/89;
summer project, 6/90 - 8/90
Dyan Louria (laboratory rotation, 1/91 - 4/91)
Sandra Wegert (laboratory rotation, 1994)
Jill Steidl (laboratory rotation, 1994)
Susan Fontaine (laboratory rotation, 1995)
Anna Lisa de la Cruz (laboratory rotation, 1998)

COMMITTEE AND SERVICE ACTIVITIES:

National

ASPET Public Information Committee 2001-2012
ASPET Committee on Public Affairs 2004 – 2012
ASPET Science Policy Committee 2012 - 2013
Member, NIDA Initial Review Group, Neurophysiology & Neuroanatomy
Research Subcommittee.1996-1998
Special Review Consultant, National Institute on Drug Abuse (NIDA) Initial
Review Group.1995-1996

The University of Arizona

University Committees/Service

Member, Committee on Neuroscience (1988 - 1998)
Member, Committee on Biophysics (1989 - 1993)
Member, Undergraduate Biology Research Program (1989 - 2000)
Graduate College Representative, Graduate College (1990 - 2002)
Reviewer/Facilitator, Small Grants Program (1998-2001)

College of Medicine Committees/Service

Member, Honors & Awards Committee (2010-2015)
Member, Student Appeals Committee (2013-2015) (2016-2019)
Member, Promotion & Tenure Committee (2008-2011)
Member, Dean's Faculty Advisory Committee (2008-2013)
Member, Continuing Medical Education Committee (2011-2014)
Member, Honor Code Committee (2004 - 2005)
Chair, Nominating Committee (2003 - 2006)
Member, Curriculum Committee (1997-2002, 2003 - 2007)
Member, Advisory Committee to Arizona Respiratory Center Training
Program
(2003 - 2005)
Chair, Standing Subcommittee for Preparation for Clinical Medicine
Course (2004-2006)
Chair, Curriculum Committee (1998-2000)
Furrow Advisory Committee, (1999-2004)
Vice-Chair, Student Progress Committee (1997-2013)
Member, Dean's Search Committee (1999-2000)
Chair, Standing Subcommittee for Human Neuroscience Course (1994-
2002)
Member, Search Committee for Head of Surgery (1998)
Member, 'Philosophy of Admissions' Statement Committee (1998)
Member, Student Progress Committee (1996-2013)
Member, Curriculum Committee (1994 - 2001)
Member, Admissions Committee (1991 - 1995)
Member, Nominating Committee (1994-1996, 2003-2010)

Member, Comprehensive Curriculum Analysis and Planning Project (CCAP),
Appraisals Task Group (1994 - 1996)
Chair, Medical Student Research Committee (1990)
Member, Medical Student Research Committee (1989 - 1991)
Substitute Interviewer, Admissions Committee, College of Medicine (1990,1991, 1996)
Member, Administrative Review Committee of Neurology (1993)

Departmental Committees

Member, Executive Committee for Graduate Program in Medical Pharmacology, 2014-2018
Tenure and Promotion Committee (2002-2008; 2013-2018)
Chair, Interdisciplinary Program in Pharmacology & Toxicology (1996-2005)
Executive Council, Interdisciplinary Program in Pharmacology & Toxicology (1991 - 2005)
Chair, Subcommittee on Curriculum, Dept. of Pharmacology/Toxicology (1989 - 1997)
Member, Pre-clinical Scientist Recruitment Committee, Department of Psychiatry (1990 - 1991)
Member, Ion-Channel Search Committee, Department of Physiology & Pharmacology (1992)
Member, Faculty Search Committee, Department of Pharmacology, Pharmacology & Toxicology (1996)
Member, Admissions Committee, Minority Summer Research Program

Miscellaneous

Speaker, McNair Achievement Program, Workshop on Successful Graduate Application (2002)
Local Advising Committee International Taurine Symposium (1997)
Faculty Mentor, MEDSTART Program (1988 and 1997)
Representative, College of Medicine, Science & Technology Week at The University of Arizona (1989)
Speaker on career developments and opportunities in basic and clinical sciences, Undergraduate Biology Research Program Brown Bag Lunch Colloquium, (1990)
Formulate and grade questions for Pharmacology & Toxicology Preliminary Examinations, (1988-2018)
Interviewer for Faculty Searches in:
Department of Neurology
Arizona Research Laboratories, Division of Neurobiology
Department of Pharmacology & Toxicology

Department of Psychiatry
Department of Physiology
Department of Pediatrics

Past Institutions

Member, Committee on Promotion & Tenure, 1986-1988, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland

Coordinator, Neuroscience Training Program, 1983-1988, Maryland Psychiatric Research Center, Baltimore, Maryland

Graduate Student President and Representative, Department of Pharmacology, University of California, School of Medicine, Los Angeles, CA, 1974

Curriculum Committee, Graduate Student Representative, Department of Pharmacology, University of California, School of Medicine, Los Angeles, CA, 1973

RESEARCH GRANTS

Prior:

National Institute on Drug Abuse
The Functional Neurobiology of Cannabinoids in Brain
UO1DA 14263
\$535,000 Total Direct
7-1-01 to 5-31-06
Edward D. French, Principal Investigator

National Institute on Drug Abuse
Visualizing Addiction for Secondary Science Education
\$806,000, 2000-2003
Steve Moore, Principal Investigator
Edward D. French, Consultant

Arizona Disease Control Research Commission
Nicotine Dependence and Dopamine Neurons: Electrophysiological and Molecular Studies
\$425,068, 9-1-00 to 9-1-03
Edward D. French, Principal Investigator

The University of Arizona
Purchase of Classroom Equipment for Instructional Computing
\$10,700, 1998-99
Edward D. French, Principal Investigator

Sandoz Research Institute

Electrophysiological Analysis of Potentially Novel Antipsychotic Drugs and Compounds with Selective Actions on the NMDA Receptor Complex
\$5,568, 10-1-93 to 9-30-98
Edward D. French, Principal Investigator

National Institute on Drug Abuse (DA09025)
Cannabinoids in Dopamine Neuron Electrophysiology
\$369,408, 3-15-95 to 2-28-98
Edward D. French, Principal Investigator

Arizona Disease Control Research Commission
Marijuana, Nicotine & Dopamine Reward Systems: A Unifying Hypothesis of Dependence
\$85,379, 8-1-95 to 7-31-98
Edward D. French, Principal Investigator

Knoll Pharmaceuticals
Assessment of Potential Abuse Liability of S-Adenosyl-L-Methionine
\$10,266, 02-01-92 – 02-01-93
Edward D. French, Principal Investigator

NOVA Pharmaceutical Corp.
Pre-Clinical Electrophysiological Analysis of Potentially Novel Antipsychotic Drugs
\$2,784, 06-01-92
Edward D. French, Principal Investigator

Office of the Vice President for Research, The University of Arizona
Marijuana and Dopamine Neuron Electrophysiology: Acute and Chronic Effects
\$4,000, 6-1-94 - 5-31-95
Edward D. French, Principal Investigator

National Institute on Drug Abuse (DA03876)
PCP and Midbrain Dopamine Neurons: Cellular Neurobiology
\$208,188, 2-1-90 to 1-31-94
Edward D. French, Principal Investigator

National Institute of Mental Health (MH44211)
Neuroscience Center for Research in Schizophrenia, Director, W.T. Carpenter, Jr
\$170,520, 3-1-89 to 2-28-94
Edward D. French, Principal Investigator

Astra Alab
Electrophysiological Analysis of Remoxipride, A Novel Antipsychotic Drug
\$11,200, 6-1-90 to 5-31-92
Edward D. French, Principal Investigator

Pfizer Corporation
Neurophysiological Analysis of Potential PCP Antagonists
\$4,470, 6-1-90 to 5-31-93
Edward D. French, Principal Investigator

National Institute on Neurological Disorders
Quinolinic Acid and Seizure Disorders
\$525,479, 10-1-90 to 9-30-93
Robert Schwarcz, Principal Investigator
Edward D. French, 1 of 3 Co-Investigators

Arizona Disease Control Research Commission
Cellular Neurobiology of Psychosis Producing Drugs of Abuse: A Model for
Schizophrenia
\$63,000, 7-1-89 to 6-30-90
Edward D. French, Principal Investigator

Biomedical Research Support Grant, The University of Arizona, College of
Medicine
Neurobiology of Phencyclidine (PCP) Self-Administration
\$6,000, 9-30-89 to 10-1-90
Edward D. French, Principal Investigator

National Institute on Neurological Diseases (NS16102-07)
Quinolinic Acid and Seizure Disorders
\$335,643, 8-1-87 to 7-31-90, Co-Investigator

Edward D. French, Co-Investigator, Robert Schwarcz, Principal Investigator
National Institute on Drug Abuse (DA03876)
PCP and a PCP-like Brain Peptide: Cellular Neurobiology
\$106,566, 9-1-84 to 3-1-88
Edward D. French, Principal Investigator

University of Maryland, Designated Research Initiative Funds
Cocaine and Dopamine Interactions Within the Central Nervous System
\$8,475, 1-1-87 to 7-1-87
Edward D. French, Principal Investigator

National Institute of Mental Health, Clinical Research Center, Pilot Study Award
Effects of Ritanserin on Midbrain Mesolimbic-Mesocortical Dopamine Neurons -
an Electrophysiological Assessment
\$9,000, 5-1-87 to 4-30-88
Edward D. French, Principal Investigator

Pharmaceutical Manufacturers Foundation Research Starter Grant
Neuronal and Synaptic Actions of Phencyclidine in Forebrain Dopamine Areas: A
Microiontophoretic Analysis
\$13,000, 1-1-87 to 12-31-89
Edward D. French, Principal Investigator

National Institute of Mental Health (MH32842)
Catecholamine Enzyme Regulation and Behavior
\$266,653, 7-1-83 to 6-30-86
Jon Stolk, Principal Investigator
Edward D. French, 1 of 2 Co-Investigators

National Institute on Neurological Diseases (R44-NS21400-02)
Excitatory Amino Acid Antagonists as Antiepileptic Drugs
\$362,322, 7-1-85 to 6-30-87
David U'Pritchard, Principal Investigator
Edward D. French, 1 of 7 Co-Investigators

National Institute of General Medical Science
The University of Arizona Initiative for Minority Ph.D.'s
\$2,245,073, 1-1-00 to 12-31-05
Maria Teresa Valez, Principal Investigator, Steering Committee (1 of 10)

PRESENTATIONS/SCHOLARLY LECTURES

- 1973 University of California, Department of Pharmacology, Los Angeles
- 1975 University of California, Department of Pharmacology, Los Angeles
- 1977 The Salk Institute, San Diego, California
- 1978 University of Pittsburgh, Physiology Department, School of Medicine,
Pennsylvania
- 1979 Merck Institute for Therapeutic Research, Neuropsychopharmacology
Division, West Point, Pennsylvania
- 1979 University of California, School of Medicine, Department of Pharmacology,
Los Angeles
- 1979 Merck Sharp and Dohme Research Laboratories,
Rahway, New Jersey
- 1980 University of Nebraska, Department of Pharmacology, Omaha, Nebraska
- 1984 Symposium, 14th Collegium Internationale Neuro-
Psychopharmacologicum Congress, Florence, Italy

- 1984 McNeil Pharmaceutical, CNS Research, Spring House, Pennsylvania
- 1984 Spring Grove Hospital Center, Baltimore, Maryland
- 1985 National Institute for Drug Abuse (NIDA), Addiction Research Center, Baltimore, Maryland
- 1985 Maryland Psychiatric Research Center, Scientific Program
- 1985 University of Maryland, School of Pharmacy, Department of Pharmacology
- 1985 Symposium: Excitatory Amino Acids and Epilepsy, Fillerval, France
- 1986 University of Maryland, Grand/Rounds, Institute of Psychiatry and Human Behavior
- 1986 The University of Arizona College of Medicine, Department of Pharmacology, Tucson, Arizona
- 1986 University of Maryland, School of Pharmacy, Department of Pharmacology and Toxicology
- 1986 Conference on Schizophrenia, Spring Grove Hospital Center, Baltimore, Maryland
- 1987 Joint US-FRENCH Seminar on Sigma Opioid/PCP-Like Compounds as Molecular Probes in Biology, Ann Arbor, Michigan
- 1988 Vollum Institute for Advanced Biomedical Research, Oregon Health Science University, Portland, Oregon
- 1989 Symposium; Phencyclidine: Basic & Chemical Pharmacology, Committee on Problems of Drug Dependence, Keystone, Colorado
- 1990 Conference for Neuroscience in Schizophrenia, Baltimore, Maryland
- 1990 Institute de Angeli, Division of Boehringer-Ingelheim, Milan, Italy
- 1991 Neuropharmacology of Drugs of Abuse, Clinical Neurological Sciences Course, The University of Arizona
- 1992 Conference for Neuroscience in Schizophrenia, Baltimore, MD
- 1992 Neurobehavioral Teratology Society Symposium on Phencyclidine, Boca Raton, FL
- 1993 Satellite Meeting of International Society for Neurochemistry; Cellular & Molecular Mechanisms of Drugs of Abuse: Cocaine and Methamphetamine, Nice, France
- 1996 Neurology, Grand Rounds, Mechanism of Action of Anticonvulsant Drugs, Department of Neurology, The University of Arizona, College of Medicine
- 1997 Introduction to Drugs of Abuse, Pima Community College, Tucson, AZ
- 1999 Neurology Grand Rounds, Antiepileptic Drugs: Mechanisms of Action, Department of Neurology, The University of Arizona, College of Medicine
- 1999 The University of Arizona Undergraduate Biology Research Program, Introduction to Pharmacology & Toxicology Graduate Programs
- 2001 Satellite meeting of International Society for Neurochemistry, Mar del Plata, Argentina
- 2003 American Dental Society of Anesthesiology, Annual Meeting, Tucson, AZ
- 2005 ASPET, Experimental Biology Meeting, San Diego, CA
- 2006 ACNP, "Neurophysiological Mapping of Toluene Sensitive Cells in the Rat Midbrain," Hollywood, FL

- 2006 CPDD, "Neurophysiological Mapping of Toluene Sensitive Cells in the Rat Midbrain", Scottsdale, AZ
- 2006 "Inhalant-induced alterations of midbrain neuron excitability", Dept. Of Pharmacology & Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX.
- 2007 California Association of Toxicologists, "Neuropharmacology of Drugs of Abuse and Addiction", Phoenix, AZ
- 2014 National Alliance on Mental Illness (NAMI) Southern Arizona Chapter, "Going to pot—a cannabis, dopamine and psychosis connections?"

SCIENTIFIC SESSIONS CHAIRED/ORGANIZED

- 1984 Session Chair, Drugs of Abuse II, Annual Meeting, Society for Neuroscience, Anaheim, California
- 1989 Symposium, Chair, Phencyclidine: Basic & Clinical Pharmacology, Committee on Problems of Drug Dependence, Keystone, Colorado

PUBLICATIONS

Monographs

French, E.D.:

Studies on the sites of morphine's actions: effects of systemic and intracerebral injections on growth hormone and corticosteroid secretion, thermoregulation and behavior in the cat. Doctoral Dissertation, University of California at Los Angeles, 1976

Book Chapters

1. Zieglgansberger, W., Siggins, G.R., **French, E.** and Bloom, F.E.: Effects of opioids on single unit activity. In: Characteristics and Functions of Opioids, (Developments in Neuroscience, Vol. 4), J.M. Van Rensselaer, L. Terenius (eds.), Elsevier/North Holland, Amsterdam, The Netherlands, 1978, pp. 75-86.
2. Bloom, F.E., Rossier, J., Battenberg, E.L.F., Bayon, A., **French, E.D.**, Henriksen, S.J. Siggins, G.R., Segal, D., Browne, R., Ling, N., Guillemin, R.: β -endorphin cellular localization, electrophysiological and behavioral effects. In: Advances in Biochemical Psychopharmacology, Vol. 18, E. Costa and M. Trabucchi (eds.), Raven Press, New York, 1978, pp. 89-109.
3. Bloom, F., Bayon, A., **French, E.**, Koob, G., Le Moal, M., Rossier, J. and Guillemin, R.: Endorphins: developmental, endocrinological, and behavioral actions. In: Molecular Endocrinology, I. MacIntyre and Szelke (eds.) Elsevier/North Holland Biomolecular Press, The Netherlands, pp. 39-55, 1979.
4. Bloom, F., Bayon, A., **French, E.**, Henriksen, S., Koob, G., Le Moal, M., Rossier, J. and Shoemaker, W.:

- Brain endorphins: developmental, electrophysiological and behavioral actions. In: Peptides - Structure and Biological Function, E. Gross and J. Meinehofer (eds.), Pierce Chemical Company, pp. 811-821, 1979.
5. Bloom, F., Bayon, A., Battenberg, E., **French, E.**, Koda, L., Koob, G., Le Moal, M., Rossier, J. and Shoemaker, W.:
Endorphins: developmental, cellular and behavioral aspects. In: Neural Peptides and Neuronal Communications, E. Costa and M. Trabucchi (eds.), Raven Press, New York, 1980, pp. 619-632.
 6. Rossier, J., **French, E.**, Guillemin, R. and Bloom, F.E.:
On the mechanisms of simultaneous release of immunoreactive β -endorphin, ACTH, and prolactin by stress. In: Neural Peptides and Neuronal Communication, E. Costa and M. Trabucchi (eds.), Raven Press, New York, 1980, pp. 363-413.
 7. Bloom, F.E., Siggins, G.R., Pittman, Q., **French, E.** and Berger, T.:
Endorphins as mediators of ethanol actions: Multidisciplinary tests. In: Advances in Endogenous and Exogenous Opioids, Kodansha Ltd., Tokyo, 1981, pp. 223-225.
 8. Bloom, F.E., Aldenhoff, J., Bakhit, C., Benoit, R., **French, E.**, Gruol, D., Koda, L., Morrison, J. and Siggins, G.:
Gut peptides in the brain: implications for therapeutics. In: Proceedings, II World Conference on Clinical Pharmacology and Therapeutics, Symposium on Neuropeptides, pp. 754-768, 1984.
 9. O'Donohue, T.L., Pert, C.B., **French, E.D.**, Pert, A., DiMaggio, D.A., Everist, H. and Quirion, R.:
Evidence for an endogenous central nervous system ligand for the phencyclidine receptor. In: Peptides, Structure and Function, V.J. Hruby and D.H. Rich (eds.) Pierce Chemical Company, Rockford, IL, pp. 433-436, 1984.
 10. Schwarcz, R., Vezzani, A. and **French, E.D.**:
Quinolinic acid induced seizures and hippocampal nerve cell loss: antagonism by -APH and kynurenic acid. In: Neurotransmitters, Seizures, and Epilepsy, III, Nistico, G., Morselli, A.Z., Lloyd, K.G., Fariello, R.G., Engel, J.Jr. (eds.), Raven Press, pp. 247-257, 1986.
 11. **French, E.D.**, Vezzani, A., Whetsell, Jr., W.O. and Schwarcz, R.:
Anti-excitotoxic actions of taurine in the rat hippocampus studied in vivo and in vitro. In: Excitatory Amino Acids and Seizure Disorders, Ben-Ari, Y. and Schwarcz, R. (eds.), Plenum Press, New York, pp. 349-362, 1986.
 12. Schwarcz, R., Speciale, C., Okuno, E., **French, E.D.** and Kohler, C.:
Quinolinic acid: a pathogen in temporal lobe epilepsy? In: Excitatory Amino Acids and Seizure Disorders, Ben-Ari, Y. and Schwarcz, R. (eds.), Plenum Press, New York, pp. 697-707, 1986.
 13. **French, E.D.**:
Effects of acute and chronic phencyclidine treatment on mesocorticolimbic A₁₀ dopamine neurons in the rat: electrophysiological and behavioral assessments. In: Sigma Opioid Phencyclidine-like Compounds as Molecular Probes in Biology,

- J.M. Kamenka, E.F. Domino, P. Geneste (eds.), NPP Books, Michigan, pp. 451-461, 1988.
14. **French, E.D.**, Lin, J.Y. and Simms, D.:
Characteristics of possible mechanisms by which phencyclidine (PCP) and PCP-like drugs alter the activity of A₁₀ dopamine neurons: Electrophysiological and behavioral studies. In: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? J.-M. Kamenka and E.F. Domino (eds.) NPP Books, Michigan, pp.445-457, 1992.

Refereed Journal Articles

1. Rossier, J., **French, E.D.**, Rivier, C., Ling, N., Guillemin, R., Bloom, F.E.:
Foot-shock induced stress increases β -endorphin levels in blood but not brain. **Nature** 270:618-620, 1977.
2. **French, E.D.**, Vasquez, S.A., George, R.:
Thermoregulatory responses of the unrestrained cat to acute and chronic intravenous administration of low doses of morphine and to naloxone precipitated withdrawal. **Life Sciences** 22:1947-1954, 1978.
3. **French, E.D.**, Vasquez, S.A., George, R.:
Potentiation of morphine hyperthermia in cats by pimozide and fluoxetine hydrochloride. **European J. Pharmacology** 48:351-356, 1978.
4. Siggins, G.R. and **French, E.D.**:
Iontophoretic and micropressure applications of ethanol and tetrahydropapaveroline depresses central neurons. **Drug and Alcohol Dependence** 4:239-243, 1979.
5. **French, E.D.**, Garcia, J.F. and George, R.:
Acute and chronic morphine effects on plasma corticosteroids and growth hormone in the cat. **Psychoneuroendocrinology** 3:237-244, 1979.
6. **French, E.D.**, Vasquez, S.A. and George R.:
Behavioral changes produced in the cat by acute and chronic intravenous morphine injection and naloxone precipitated withdrawal. **European J. Pharmacology** 57:387-398, 1979.
7. Rossier, J., **French, E.**, Gros, C., Minick, S., Guillemin, R. and Bloom, F.E.:
Adrenalectomy, dexamethasone or stress alters opioid peptide levels in rat anterior pituitary but not intermediate lobe or brain. **Life Sciences** 25:2105-2112, 1979.
8. Zieglgansberger, W., **French, E.D.**, Siggins, G.R. and Bloom, F.E.:
Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons. **Science** 205:415-417, 1979.
9. **French, E.D.**:
Dexamethasone blocks morphine-induced hypothermia in restrained rats. **Life Sciences** 25:1583-1590, 1979.
10. Rossier, J., **French, E.**, Rivier, C., Shibasaki, T., Guillemin, R. and Bloom, F.E.:

- Stress-induced release of prolactin: blockade by dexamethasone and naloxone may indicate β -endorphin mediation. **Proceedings National Academy of Sciences, USA** 77:666-669, 1980.
12. **French, E.D.**, Siggins, G.R. and Bloom, F.E.:
An iontophoretic survey of opioid peptide actions in rat limbic system: in search of opiate epileptogenic mechanisms. **Regulatory Peptides** 1:127-146, 1980.
 13. Schwarcz, R., Aldinio, C., **French, E.D.** and Collins, J.F.:
Neurotoxic and convulsant effects of ibotenic acid are antagonized by (-) 2-amino-7-phosphonoheptanoic acid. **Neuroscience** 7:118, 1982.
 14. Berger, T., **French, E.D.**, Siggins, G.R. and Bloom, F.E.:
Ethanol and some tetrahydroisoquinolines alter the discharge of rat hippocampal neurons in vivo when applied by microelectroosmosis or pressure: relationship to opiate actions. **Pharmacology Biochemistry & Behavior** 17:813-821, 1982.
 15. **French, E.D.**, Aldinio, C. and Schwarcz, R.:
Electroencephalographic seizures and neuronal degeneration: relationships investigated by intrahippocampal kainic acid in the unanesthetized freely behaving rat. **Neuroscience** 7:2525-2536, 1982.
 16. Siggins, G.R., Berger, T., **French, E.D.**, Shier, T. and Bloom, F.E.:
Ethanol, salsolinol and tetrahydropapaveroline alter the discharge of neurons in several brain regions: comparison to opioid effects. **Progress Clinical & Biological Research** 90:275-287, 1982.
 17. **French, E.D.** and Zieglgansberger, W.:
The excitatory response of in vitro hippocampal pyramidal cells to morphine and methionine enkephalin maybe mediated by different receptor populations. **Experimental Brain Research** 48:238-244, 1982.
 18. Zieglgansberger, W., **French, E.D.**, Mercuri, N., PeLayo, F. and Williams, J.T.:
Multiple opiate receptors on neurons of the mammalian central nervous system. In vivo and in vitro studies. **Life Sciences** 31:2343-2346, 1982.
 19. Aldinio, C., **French, E.D.** and Schwarcz, R.:
The effects of intrahippocampal ibotenic acid and their blockade by (-) 2-amino-7-phosphonoheptanoic acid: morphological and electroencephalographical analysis. **Experimental Brain Research** 51:36-41, 1983.
 20. Schwarcz, R., Brush, G.S., Foster, A.C. and **French, E.D.**:
Seizure activity and lesion following intrahippocampal quinolinic acid. **Experimental Neurology** 84:1-17, 1984.
 21. **French, E.D.** and Vantini, G.:
Phencyclidine-induced locomotor activity in the rat is blocked by a 6-hydroxydopamine lesion of the nucleus accumbens: comparisons to other psychomotor stimulants. **Psychopharmacology** 82:82-88, 1984.
 22. Foster, A.C., Vezzani, A., **French, E.D.** and Schwarcz, R.:
Kynurenic acid blocks neurotoxicity and seizures in rats by the related brain metabolite quinolinic acid. **Neuroscience Letters** 48:273-278, 1984.
 23. **French, E.D.**, Foster, A.C., Vezzani, A. and Schwarcz, R.:

- Quinolinic acid and kynurenic acid, two endogenous tryptophan metabolites with potential links to epileptic disorders. **Clinical Neuropharmacology** 7:456-457, 1984.
24. Schwarcz, R., Foster, A.C., **French, E.D.**, Whetsell, Jr., W.O. and Kohler, C.: Excitotoxic models for neurodegenerative disorders. **Life Sciences** 35:19-32, 1984.
 25. Quirion, R., DiMaggio, D.A., **French, E.D.**, Contreras, P.C., Shiloach, J., Pert, C.B., Everist, H., Pert, A. and O'Donohue, T.L.: Identification of an endogenous peptide ligand for the phencyclidine receptor. **Peptides** 5:967-973, 1984.
 26. Vezzani, A., Ungerstedt, U., **French, E.D.** and Schwarcz, R.: In vivo brain dialysis of amino acids and simultaneous EEG measurements following intrahippocampal quinolinic acid injection: evidence for a dissociation between neurochemical changes and seizures. **J. Neurochemistry** 45:335-344, 1985.
 27. **French, E.D.**, Vezzani, A., Whetsell, W.O. and Schwarcz, R.: Anti-excitotoxic effects of taurine in the rat hippocampus in vitro and in vivo. **Epilepsia** 26:205-207, 1985.
 28. Schwarcz, R., Speciale, C., Okuno, E., **French, E.D.**, and Kohler, C.: Quinolinic acid: a pathogen in seizure disorder. **Advances in Experimental Medicine & Biology** 203: 697-707, 1986.
 29. **French, E.D.**, Vantini, G., Pilapil, C. and Quirion, R.: Phencyclidine binding sites in the nucleus accumbens and PCP-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. **European J. Pharmacology** 116:1-9, 1985.
 30. **French, E.D.**: Effects of N-allylnormetazocine (SKF 10,047), phencyclidine and other psychomotor stimulants in the rat following a 6-hydroxydopamine lesion of the ventral tegmental area. **Neuropharmacology** 25:447-450, 1986.
 31. **French, E.D.**: Effects of phencyclidine on ventral tegmental A₁₀ dopamine neurons in the rat. **Neuropharmacology** 25:241-248, 1986.
 32. **French, E.D.**, Jacobson, A.C. and Rice, K.C.: Metaphit, a proposed phencyclidine antagonist, blocks PCP-induced locomotor behavior through mechanisms unrelated to specific antagonism of PCP receptors. **European J. Pharmacology** 140:267-274, 1987.
 33. Siggins, G.R., Pittman, Q.J. and **French, E.D.**: Effects of ethanol on CA1 and CA3 pyramidal cells in the hippocampal slice preparation: an intracellular study. **Brain Research** 414:22-34, 1987.
 34. Siggins, G.R., Bloom, F.E., **French, E.D.**, Madamba, S.G., Mancillas, J., Pittman, Q.J. and Rogers, J.: Electrophysiology of ethanol on central neurons. **Annals, NY Academy of Science** 492:350-366, 1987.
 35. Schwarcz, R., Speciale, C. and **French, E.D.**:

- Hippocampal kynurenines as etiological factors in seizure disorders. **Polish J. Pharmacology** 39:485-494, 1987.
36. **French, E.D.:** Effects of acute and chronic phencyclidine (PCP) on the A₁₀ dopaminergic mesolimbic system: electrophysiological and behavioral correlates. **Neuropharmacology** 27:791-798, 1988.
37. Ceci, A., Smith, M. and **French, E.D.:**
Activation of the A₁₀ mesolimbic system by the sigma receptor agonist (+)SKF 10,047 is selectively antagonized by the novel putative antipsychotic rimcazole. **European J. Pharmacology** 154:53-57, 1988.
38. Ceci, A. and **French, E.D.:**
Effects of phencyclidine on ventral tegmental A₁₀ dopamine neurons in rats with lesions of the prefrontal cortex, accumbens and dorsal raphe nuclei. **Annals, NY Academy of Science** 537:500-501, 1988.
39. Ceci, A. and **French, E.D.:**
Phencyclidine-induced activation of ventral tegmental A₁₀ dopamine neurons is differentially affected by lesions of the nucleus accumbens and medial prefrontal cortex. **Life Sciences** 45:637-646, 1989.
40. **French, E.D.,** Kamenka, J.-M. and Lin, J.-Y.:
Bi-modal effects of phencyclidine on A₁₀ dopamine neurons results from diverse actions at the PCP-receptor and dopamine uptake complex. **European J. Pharmacology** 183(2):428-429, 1990.
41. **French, E.D.** and Ceci, A.:
Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A₁₀ dopamine neurons. **Neuroscience Letters** 119:159-162, 1990.
42. **French, E.D.,** Ferkany, J., Abreu, M. and Levenson, S.:
Effects of Competitive N-Methyl-D-Aspartate Antagonists on Midbrain Dopamine Neurons: An Electrophysiological and Behavioral Comparison to Phencyclidine. **Neuropharmacology** 30:1039-1046, 1991.
43. McMaster, O.G., Du, F., **French, E.D.** and Schwarcz, R.:
Focal Injection of aminooxyacetic acid produces seizures and lesions in rat hippocampus: Evidence for mediation by NMDA receptors. **Experimental Neurology** 113:378-385, 1991.
44. **French, E.D.:** Competitive NMDA receptor antagonists attenuate phencyclidine-induced excitations of A₁₀ dopamine neurons. **European J. Pharmacology** 271:1-7. 1992.
45. **French, E.D.,** Mura, A. and Wang, T.:
MK-801, phencyclidine (PCP) and PCP-like drugs increase burst firing in rat A₁₀ dopamine neurons: Comparison to competitive NMDA antagonists. **Synapse** 13:108-116, 1993.
46. Wang, T. and **French, E.D.:**
Electrophysiological evidence for the existence of NMDA and non-NMDA receptors on rat ventral tegmental dopamine neurons. **Synapse** 13:270-277, 1993.
47. Wang, T. and **French, E.D.:**

- Effects of phencyclidine on spontaneous and excitatory amino acid-induced activity of ventral tegmental dopamine neurons: An extracellular in vitro study. **Life Sciences** 53:49-56, 1993.
48. Wang, T. and **French, E.D.**: L-glutamate excitation of A₁₀ dopamine neurons is preferentially mediated by activation of NMDA receptors. Extra- and intracellular electrophysiological studies in brain slices. **Brain Research** 627:299-306, 1993.
 49. McMaster, O.G., Baran, H., Wu, H.-Q., Du, F., **French, E.D.** and Schwarcz, R.: γ -acetylenic GABA produces axon-sparing neurodegeneration after focal injection into the rat hippocampus. **Experimental Neurology** 124:184-191, 1993
 50. **French, E.D.**: Phencyclidine and the midbrain dopamine system: Electrophysiology and behavior. **Neurotoxicology and Teratology** 16:355-362, 1994.
 51. **French, E.D.**, Lopez, M., Peper, S., Kamenka, J-M. and Roberts, D.C.S.: The self-administration of BTCP, a phencyclidine derivative with potent dopamine uptake properties: Comparison to PCP, TCP and cocaine using a progressive ratio schedule of reinforcement. **Behavioral Pharmacology** 6:223-228, 1995.
 52. Wang, T., O'Connor, W.T., Ungerstadt, U. and **French, E.D.**: N-methyl-D-aspartic acid biphasically regulates the biochemical and electrophysiological responses of A₁₀ dopamine neurons in the ventral tegmental area: In vivo microdialysis and in vitro electrophysiological studies. **Brain Research** 666:255-262, 1995.
 53. Wang, T. and **French, E.D.**: NMDA Kainate and AMPA depolarize nondopamine neurons in the rat ventral tegmentum. **Brain Research Bulletin** 36:39-43, 1995.
 54. Reid, L.D. Gillick, S.D., Menkens, K.A., **French, E.D.**, Bilsky, E.J. and Porreca, F.: Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. **Neuroreport** 6:1281-1284, 1995.
 55. Bourland, J.A. and **French, E.D.**: Effects of remoxipride, an atypical antipsychotic, on cocaine self-administration in the rat using fixed - and progressive - ratio schedules of reinforcement. **Drug and Alcohol Dependence** 40:111-114, 1995.
 56. Ranaldi, R., **French, E.** and Roberts, D.C.S.: Systemic pretreatment with MK-801 increase break points on a progressive ratio schedule reinforced by intravenous cocaine in rats. **Psychopharmacology** 128:83-88, 1996.
 57. **French, E.D.**, Dillon, K. and Ali, S.F.: Effects of Ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons: **Pharmacology Letters** 59:PL199-205, 1996.
 58. **French, E.D.**, Dillon, K. and Wu, X.: Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. **NeuroReport** 8:649-652, 1997.
 59. **French, E.D.**: Δ^9 -tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. **Neuroscience Letters** 226:159-162, 1997.
 60. Riegel, A. and **French, E.D.**: Acute toluene induces biphasic changes in rat spontaneous locomotor activity which are blocked by remoxipride. **Pharmacology, Biochemistry & Behavior** 62:399-402, 1999.

61. Riegel, A. and **French, E.D.**: An electrophysiological analysis of rat ventral tegmental dopamine neuronal activity during acute toluene exposure. **Pharmacology & Toxicology** 85:37-43, 1999.
62. Riegel, A. and **French, E.D.**: The susceptibility of rat non-dopamine ventral tegmental neurons to inhibition during toluene exposure. **Pharmacology & Toxicology** 85:44-46, 1999.
63. Wu, X. and **French, E.D.**: Effects of chronic Δ^9 -tetrahydrocannabinol on rat midbrain dopamine neurons: An electrophysiological assessment. **Neuropharmacology** 39:391-398, 2000.
64. Yin, R. and **French, E.D.**: A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: An *in vitro* electrophysiological study. **Brain Research Bulletin** 51:507-514, 2000.
65. A.C. Riegel and **French, E.D.**: Abused inhalants and central reward pathways: Electrophysiological and behavioral studies in the rat. **Annals N.Y. Acad. Science** 965, 2002.
66. Riegel, A.C., Ali, S.F. and **French, E.D.**: Toluene-induced locomotor activity is blocked by 6-hydroxydopamine lesions of the nucleus accumbens and the mGLUR2/3 agonist LY379268. **Neuropsychopharmacology** 28:1440-1447, 2003.
67. **French, E.D.**: Academic pharmacologists: confronting new challenges in educational programs of graduate and health care professionals. **The Journal of Pharmacology and Experimental Therapeutics** 309:441-443, 2004.
68. Riegel, A.C., Ali, S.F., Torinese, S. and **French, E.D.**: Repeated exposure to the abused inhalant toluene alters levels of neurotransmitters and generates peroxynitrite in nigrostriatal and mesolimbic nuclei in rat. **Annals N.Y. Acad. Science** 1025:1-9, 2004.
69. Riegel, A.C., Zapata, A., Shippenberg, T.S. and **French, E.D.**: The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. **Neuropsychopharmacology**, 32:1558-1569, 2007.
70. Gerdeman, G.L., Schechter, J.B. and **French, E.D.**: Context-specific reversal of cocaine sensitization by the CB₁ cannabinoid receptor antagonist rimonabant. **Neuropsychopharmacology**, 33:2747-2759, 2008.
71. Fioravanti, B., Kasasbeh, A., Edelmayer, R., Skinner, D., Hartings, J.A., Burkland, R.D., DeFelice, M., **French, E.D.**, Dussor, G.O., Dodick, D.W., Porreca, F. and Vanderah, T.W. Evaluation of cutaneous allodynia following induction of cortical spreading depression in freely moving rats. **Cephalalgia** DOI:1177/0333 10241-14106, 2009.
72. Corral-Frias, N.S., **FRENCH, E.D.** and Fellows, J-M.: Involvement of the ventral tegmental area in a rodent model of post-traumatic stress disorder. **Neuropsychopharmacology** 38: 350-363, 2012.
73. Janezic, E.M., Uppalapati, S., Nagl, S., Contreras, M., **French, E.D.** and Fellous, J-M. Beneficial effects of chronic oxytocin administration and naïve social co-housing in a rodent model of post-traumatic stress disorder. **Behavioral Pharmacology** 27: 704-717, 2016.

Reviews

1. **French, E.D.** and Williams, J.T.: Electrophysiological Evaluations of Opioid Systems - Extracellular and Intracellular Approaches. In: **Methods in Enzymology, V. "Neuroendocrine Peptides"**, 168:103-128, 1989.
2. **French, E.D.**, Levenson, S. and Ceci, A.: Characterization of the actions of phencyclidine on midbrain neurons. **NIDA Res. Monograph, Problems of Drug Dependence** 95:255-263, 1990.
3. Riegel, A. and **French, E.D.**: Toluene alters rat A₁₀ DA and non-DA neurons through a dependent mechanism. **NIDA Monograph Series, 1997**

Proceedings

1. French, E.D., Garcia, J.F., George, R.: Intracerebral morphine and naloxone effects on growth hormone and cortisol in naive and morphine dependent cats. **Proceedings of the Western Pharmacology Society** 17:159-163, 1974.
2. **French, E.D.**, Vasquez, S.A., George, R.: Acute and chronic morphine and withdrawal from morphine on temperature in the cat. **Proceedings of the Western Pharmacology Society** 19:273-277, 1976.
3. **French, E.D.**: Academic Pharmacologists: Meeting the educational needs of graduate programs and the health care professions. **Supplement to Proceedings of the Western Pharmacology Society** 42:29-31, 1999.

Abstracts

1. **French, E.D.**, Vasquez, S.A., George, R.: Potentiation of morphine hyperthermia in cats by pimozide and fluoxetine hydrochloride (Lilly 110140). **Federation Proceedings** 5(3):263, 1976.
2. **French, E.D.**, Siggins, G.R., Henriksen, S.J., Ling, N.: Iontophoresis of opiate alkaloids and endorphins accelerates hippocampal unit firing by a non-cholinergic mechanism: correlation with EEG seizures. **Society for Neuroscience**, pg. 291, 1977.
3. Zieglgansberger, W., **French, E.D.**, Siggins, G.R., Bloom, F.E.: Opiates and opioid peptides may excite hippocampal pyramidal neurons (HPN) by disinhibition. **International Narcotic Research Conference**, July 23-27, 1978.
4. **French, E.D.**, Bloom, F.E., Rivier, C., Guillemin, R., Rossier, J.: Morphine or stress-induced increases of plasma β -endorphin and prolactin are prevented by dexamethasone pretreatment. **Society for Neuroscience**, 1978.
5. Siggins, G.R., Zieglgansberger, W., **French, E.**, Ling, N., Bloom, F.: Opiates and opioid peptides may excite hippocampal (HPC) pyramidal neurons (HPN) by inhibiting adjacent inhibitory interneurons. **Society for Neuroscience**, 1978.
6. Henriksen, S.J., McCoy, F., **French, E.**, Bloom, F.E.: β -endorphin induced epileptiform activity: effects of lesions and specific opiate receptor agonists. **Society for Neuroscience**, 1978.

7. Zieglgansberger, W., **French, E.**, Siggins, G.R., Bloom, F.: Opiates and opioid peptides may cause excitation of hippocampal pyramidal neurons (HPN) by disinhibition. **German Physiological Society**, Herbst (Fall), 1978.
8. Newlin, S.A., **French, E.D.**, Berger, T. and Bloom, E.F.: Ethanol prolongs the time course of recurrent inhibition in the hippocampus in response to commissural fiber activation. **Society for Neuroscience**, 1979.
9. George, R., **French, E.** and Vasquez, S.A.: Naloxone-induced seizures and its reversal by morphine in rats, rabbits and cats. **American Society of Pharmacology and Experimental Therapeutics**, 1979.
10. Siggins, G.R., Rogers, J., Schulman, J., **French, E.** and Bloom, F.E.: Response of cerebellar purkinje cells to locally or intraperitoneally administered ethanol. **XXVIII International Congress of Physiological Science**, 1980.
11. **French, E.D.**, Berger, T.W., Siggins, G.R., Shier, T.W. and Bloom, F.E.: Comparison of the effects of ethanol, tetrahydroisoquinolines (TIQ's) and opiates on neuronal activity in brain: an iontophoretic and micro-pressure study. **Society for Neuroscience**, 1980.
12. Aldinio, C., **French, E.D.** and Schwarcz, R.: Seizure and neuronal degeneration: relationships investigated by intrahippocampal kainic and ibotenic acid. **Society for Neuroscience**, 1981.
13. Aldinio, C., Toffano, G., **French, E.D.** and Schwarcz, R.: Electroencephalographic and histological assessment of picomole amounts of kainic acid injected into the hippocampus of the unanesthetized freely behaving rat. **XXI Congress of the Italian Society of Pharmacology**, 1982.
14. Brush, G.S., Vezzani, A., Foster, A.C., **French, E.D.** and Schwarcz, R.: EEG and neuropathological consequences of intrahippocampal quinolinic acid. **Society for Neuroscience**, 1983.
15. Vantini, G., Perry, B., Guchhait, R., **French, E.D.**, U'Prichard, D. and Stolk, J.: Brain epinephrine-containing neurons: functional role in regulating medulla-pons noradrenergic neurons. **Society for Neuroscience**, 1983.
16. **French, E.D.** and Vantini, G.: Phencyclidine-induced locomotor activity in the rat is blocked by a 6-hydroxydopamine lesion of the nucleus accumbens or ventral tegmental area: comparisons to other psychomotor stimulants. **Society for Neuroscience**, 1984.
17. Schwarcz, R., Brush, G.S., Foster, A.C. and **French, E.D.**: Intrahippocampal quinolinic acid as a model for temporal lobe epilepsy. **15th Epilepsy International Symposium**, 1983.
18. Vantini, G., Stolk, J.M., U'Prichard, D.C. and **French, E.D.**: Locus coeruleus α_2 -receptor sensitivity assessed in two different rat strains: electrophysiological and biochemical correlates. **Society for Neuroscience**, 1984.
19. Siggins, G.R. and **French, E.D.**: Pro-somatostatin peptides alter the discharge rate of rat cortical and hippocampus neurons in vivo: an iontophoretic study. **Society for Neuroscience**, 1984.
20. **French, E.D.**, Vantini, G., Contreras, P., Pilapil, C. and Quirion, R.: Phencyclidine (PCP) binding in the nucleus accumbens (NAc) and PCP-induced

- hyperactivity are decreased following 6-hydroxydopamine (6-OHDA) lesions of the mesolimbic dopamine system. **Society for Neuroscience**, 1984.
21. Brush, G. and **French, E.D.**: An electrophysiological assessment of the effects of systemically and iontophoretically applied phencyclidine (PCP) on ventral tegmental area (VTA) A₁₀ dopamine neurons. **Society for Neuroscience**, 10:6, 1984.
 22. Vezzani, A., **French, E.D.**, Whetsell, Jr., W.O. and Schwarcz, R.: Quinolinic acid and taurine: interactions in the brain examined in vivo and in vitro. **Society for Neuroscience**, 15:339, 1985.
 23. **French, E.D.**: A comparison of the effects of acute and chronic phencyclidine on the activity of ventral tegmental A₁₀ neurons, locomotor and ataxic behavior in the rat. **Society for Neuroscience**, 12, 1986.
 24. Brush, G.S., Schwarcz, R. and **French, E.D.**: Homotopic protection against kainate neurotoxicity following unilateral lesion of the nucleus accumbens with kainic acid. **Society for Neuroscience**, 12, 1986.
 25. **French, E.D.**: Metaphit, a proposed phencyclidine (PCP) antagonist, may block PCP-induced behaviors through a presynaptic mechanism. **Pharmacologist**, 28:190, 1986.
 26. **French, E.D.**: Phencyclidine-induced changes in A₁₀ dopamine neuronal activity and locomotor behavior in rats chronically treated with PCP. **Pharmacol. Biochem. Behav.**, 28, 1987.
 27. Ceci, A. and **French, E.D.**: Disruption of central serotonergic function blocks the activation of A₁₀ but not A₉ dopamine neurons by phencyclidine (PCP). **Society for Neuroscience**, 1988.
 28. **French, E.D.**, Smith, M. and Ceci, A.: Rimcazole (RMZ), a novel antipsychotic, blocks the activation of A₁₀ dopamine neurons by phencyclidine and (+) SKF 10,047, a σ -agonist. **Society for Neuroscience**, 1988.
 29. **French, E.D.** and Ceci, A.: Phencyclidine and σ -psychotomimetic drugs activate mesocorticolimbic dopamine neurons through the non-haloperidol sensitive phencyclidine binding site. **Schizophrenia Research**, 2:184, 1989.
 30. Levenson, S. and **French, E.D.**: Effects of phencyclidine (PCP), a non-competitive, and NPC 12626, a competitive N-methyl-D-aspartate antagonist on mesolimbic dopamine systems: an electrophysiological and behavioral comparison. **Society for Neuroscience**, 1989.
 31. McMaster, O.G., Du, F., **French, E.D.** and Schwarcz, R.: Focal injection of aminoxyacetic acid produces seizures and lesions in rat hippocampus: evidence for mediation by NMDA receptors. **Society for Neuroscience**, 1990.
 32. **French, E.D.**, Kamenka, M.-M and Lin, J.Y.: Bimodal effects of phencyclidine on A₁₀ dopamine neurons results from diverse actions at the PCP-receptor and dopamine uptake complex. **XI International Congress on Pharmacology**, 1990.
 33. Levenson, S. and **French, E.D.**: Delta-9-tetrahydrocannabinol stimulates the activity of ventral tegmental A₁₀ dopamine neurons in the rat. **Society for Neuroscience**, 1990.

34. **French, E.D.:** Phencyclidine-induced activation of A₁₀ dopamine neurons is blocked by competitive NMDA-receptor antagonists. **Society for Neuroscience**, 1991.
35. McMaster, O.G., Baran, H., Du, F., Wu, H.Q., **French, E.D.** and Schwarcz, R.: Gamma-acetylenic GABA causes excitotoxic lesions in the rat hippocampus. **Society for Neuroscience**, 1992.
36. Wang, T. and **French, E.D.:** Electrophysiological evidence of NMDA, kainate (Ka) and AMPA receptors on VTA dopamine neurons in the rat. **Society for Neuroscience**, 1992.
37. **French, E.D.:** Mechanisms by which phencyclidine alters dopamine neuronal activity: Electrophysiological and behavioral studies. **Teratology** 45(5):523, 1992.
38. Ingersoll, R.T., Montgomery, E.B., **French, E.D.** and Aposhian, H.V.: Lateral choroid plexus protects the CSF from elevated blood manganese while intrathecal manganese administration induces neurotoxicity in the rat. **Society for Neuroscience**, 1993.
39. Wang, T. and **French, E.D.:** L-glutamate excitation of VTA dopamine neurons is preferentially mediated by activation of NMDA receptors: Extra- and intracellular electrophysiology in brain slices. **Society for Neuroscience**, 1993.
40. Menkens, K.A., **French, E.D.**, Porreca, F., Hubbell, C. L. and Reid, L.D.: Effects of naltrindole on cocaine's self-administration in the rat: **College on Problems of Drug Dependence**, 1994.
41. **French, E.D.:** Effects of atypical and typical neuroleptics on phencyclidine (PCP)-induced stimulation of A₁₀ dopamine (DA) neurons. **Society for Neuroscience**, 1994
42. Wang, T. and **French, E.D.:** Kainic acid inhibits a hyperpolarization-induced cation current in rat ventral tegmental (VTA) dopamine neurons. **Society for Neuroscience**, 1994.
43. Nichols, M.L., Bian D., Ossipov, M.H., **French, E.D.** and Porreca, F.: Modulation of spinal opioid efficacy in a model of neuropathic pain in rats: **Society for Neuroscience**, 1995.
44. O'Connor, W.T., Wang, T., **French, E.D.** and Ungerstadt, U.: Perfusion with N-methyl-D-aspartate in rat ventral tegmental area biphasically regulates local GABA release and mesostriatal dopamine release in vivo. **Society for Neuroscience**, 1995.
45. **French, E.D.**, Dillon, K. and Wu, XiaoFang: Effects of cannabinoids on the electrophysiological activity of midbrain dopamine neurons. **College on Problems of Drug Dependence**, 1995.
46. Riegel, A.C. and **French, E.D.:** Toluene alters rat VTA dopamine and non-DA neurons through a dose-dependent mechanism. **College on Problems of Drug Dependence**, 1997.
47. Riegel, A.C. and **French, E.D.:** Hypoxia alters rat A₁₀ VTA activity (excitation of non-DA and inhibition of DA): Implications for inhalant abuse. **Society for Neuroscience**, 1997.
48. Yanochko, G.M., **French, E.D.**, Regan, J.W., Vaillancourt, R.R. and Yool, A.J.:

- Channel properties of big brain expressed in *Xenopus oocytes*. **Society for Neuroscience**, 1999.
49. Yin, R., Wu, X., and **French, E.D.**: Cannabinoid-induced excitation of midbrain dopamine (DA) neurons: In vivo and in vitro studies. **Western Pharmacology Society**, 2000.
 50. Riegel, A. and **French, E.D.**: The abused inhalant toluene has stimulatory effects on VTA dopamine (DA) and non-DA neurons in vitro. **College on Problems of Drug Dependence**, 2000.
 51. Malan, T., Riegel, A. and **French, E.D.**: The behavioral stimulant effect of the abused inhalant toluene is reduced by nucleus accumbens lesions and activation of MGLU receptors. **Society for Neuroscience**, 2001.
 52. Riegel, A. and **French, E.D.**: Behavioral tolerance from repeated toluene exposure is paralleled by reduced VTA dopamine spontaneous neuronal activity & responsiveness to toluene, and increased sensitivity of *non*-DA neurons to NMDA. **Society for Neuroscience**, 2001.
 53. **French, E.D.** and Riegel, A.: The excitatory effects of the abused inhalant toluene in rat VTA neurons *in vitro* appears not to be mediated by NMDA receptor activation. **Society for Neuroscience**, 2001.
 54. George, A.A., Wilkens, L.L., Kuo Y.P., Lucero, Sandoval, K., **French, E.D.** and Lukas, R.J. Radioligand binding autoradiography and in situ hybridization to detect nicotinic acetylcholine receptors (nAChR) and their subunit transcripts in cell lines and mouse brain. **Society for Neuroscience**, 2001.
 55. **French, E.D.**, Riegel, A., Torinese, S., Ali, S. Changes in dopaminergic, serotonergic, and peroxynitrite related neurotransmission along nigrostriatal and mesolimbic axes following acute and subchronic administration of the abused inhalant toluene. **Society for Neuroscience**. 2002.
 56. Sandoval, K.E., **French, E.D.**, George, A.A., Kuo Y.P., Lukas, R.J. Exploring the role of neuronal nicotinic acetylcholine receptors on ventral tegmental area dopamine neurons in the ICR mouse: An *in vivo* electrophysiological study. **Society for Neuroscience**. 2002.
 57. **French, E.D.** and Sandoval, K. Determination of the ICR mouse as a nicotine-sensitive or nicotine-resistant strain of mice. **Society for Neuroscience**. 2003.
 58. Sandoval, K. and **French, E.D.**
An electrophysiological assessment of the ventral tegmental area (VTA) dopamine neuronal response to nicotine in mice chemically treated with nicotine. **Society for Neuroscience**, 2003.
 59. George, A.A., Kuo, Y-P., Sandoval, K., **French, E.D.** and Lukas, R.J. Detection and cellular distribution of nicotinic acetylcholine receptors and their subunit transcripts in mouse midbrain nuclei. **Society for Neuroscience**, 2003
 60. Riegel, A., Ali, S., Torinese, S., **French, E.D.**
Acute and subchronic administration of the abuse inhalant toluene alters levels of neurotransmitters and peroxynitrite in nigrostriatal and mesolimbic nuclei. **Satellite Meeting of International Society for Neurochemistry**, Kyoto Japan, 2003.
 61. Gerdeman, G.L., Hoffman, A.F., **French, E.D.** and Lupica, C.R.

- Electrical stimulation of endocannabinoid signaling reveals diversity of cannabinoid-sensitive synapses. **International Cannabinoid Research Society, 13th Annual Symposium**, 2003.
62. Gerdeman, G.L., Schechter, J.B. and **French, E.D.**: Investigating cannabinoids and behavioral sensitization to psychostimulants. **International Cannabinoid Research Society, 14th Annual Symposium, 2005.**
63. Thome, A., Schechter, J.B. and **French, E.D.**: Getting Lost: The effects of cannabinoids on spatial representation in the rodent hippocampus. **International Cannabinoid Research Society, Symposium on the Cannabinoids**, 2005.
64. Gerdeman, G.L., Schechter, J.B. and **French, E.D.**: Inhibition of stimulus-response (habit) learning by striatal injection of the CB₁ antagonist rimonabant. **Abstract Submitted to the International Cannabinoid Research Society**, 2006.
65. Corral-Frias, N., Valdes, J., **French, E.D.**: Latent effects of inescapable foot shock on ventral tegmental area dopamine cell activity. **Society for Neuroscience**, 2008.
66. Corral-Frias, N., Valdes, J., **French, E.**, and Fellous-J-M. Latent effects of stress in rats! Influence on ventral tegmental area dopamine excitability. **Mexican Psychology Congress**, 2008.
67. Fioravanti, B., Edelmayer, R., Hartings, J.A., **French, E.D.**, Porreca, F. and Vanderah, T.W. Behavioral changes in a rat model of cortical spreading depression. **Society for Neuroscience.**, 2008
68. Largent-Milnes, T., Yamamoto, T., Campos, C., Corral-Frias, N., Jimenez-Andrade, J., David, P., Ma, S-W., Mantyh, P., **French, E.D.**, Davis, T., Lai, J., Hruby, V., Porreca, F. and Vanderah, T. Dual acting opioid agonist/NK₁ antagonist does not produce antinociceptive tolerance or reward in an animal model of neuropathic pain. **Society for Neuroscience**, 2009.
69. Corral-Frias, N., Cremer, J., Valdes, J., **French, E.**, Fellous, J-M. Role of the ventral tegmental area in anxiety disorders: electrophysiological and reversible inactivation studies in a rodent model of post-traumatic stress disorder. **Society for Neuroscience**, 2009.
70. Corral-Frias, N.S., Brookshire, S.W., Edelman-Vogelsang, K., Valdes, J.L., **French, E.D.**, Fellous, J.M. Behavioral and electrophysiological studies of the ventral tegmental area after traumatic stress. **Society for Neuroscience**, 2010
71. Edelman-Vogelsong, Lahood, R.P., Corral-Frias, N., **French, E.D.**, Fellous, J-M. Sex differences in a rat model of post-traumatic stress disorder. **Society for Neuroscience**, 2011.
72. Skinner, D.P., Kasabeh, A., Fiorvanti, B., **French, E.**, Dussor, G.O., Porreca, F., Vanderah, T.W. Evaluation of cutaneous allodynia following induction of cortical spreading depression in freely moving rats. Society for Neuroscience, 2011.
73. Janezic, E., LaHood, R., Stidd, D., Langevin, J-P., **French, E.**, Fellous, J-M. Pharmacological and deep brain stimulation treatments in a rodent model for post-traumatic stress disorder. Society for Neuroscience, 2013.

74. Janezic, E., Nagh, S., Uppalapati, S., **French, E.**, Fellous, J-M. Oxytocin and social bonding as treatments in a rodent model of post-traumatic stress disorder. Society for Neuroscience, 2014.

FORENSIC PHARMACOLOGY

I have consulted for the courts and for attorneys in civil and criminal matters since 1994 and have been qualified as an expert witness by the courts during that time to provide expert testimony under the relevant rules of evidence (state and federal courts). Since 2017, I have testified in more than eighteen state and federal court cases in Arizona, New Mexico, and Nevada.